Fig. 3From: Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective studyScatter plot showing NAbs % inhibition at V1, V2, V3, and V4 (X: sampling time; Y: NAbs %inhibition)Back to article page